Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Patel, Poulam M.; Ottensmeier, Christian H.; Mulatero, Clive; Lorigan, Paul C.; Plummer, Ruth; Pandha, Hardev; Elsheikh, Somaia; Hadjimichael, Efthymios; Villasanti, Naty; Adams, Sally E.; Cunnell, Michelle; Metheringham, Rachael L.; Brentville, Victoria A.; Machado, Lee; Daniels, Ian; Gijon, Mohamed; Hannaman, Drew; Durrant, Lindy G.

Published in

Taylor and Francis Group, OncoImmunology, 6(7), 2018

DOI: 10.1080/2162402x.2018.1433516

Tools

Export citation

Search in Google Scholar

Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Journal article published in 2018 by Poulam M. Patel, Christian H. Ottensmeier, Clive Mulatero, Paul C. Lorigan, Ruth Plummer

, Hardev Pandha, Somaia Elsheikh, Efthymios Hadjimichael, Naty Villasanti, Sally E. Adams, Michelle Cunnell, Rachael L. Metheringham, Victoria A. Brentville, Lee Machado

, Ian Daniels

and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving forbidden

Policy details

Data provided by

Abstract

A DNA vaccine, SCIB1, incorporating two CD8 and two CD4 epitopes from TRP-2/gp100 was evaluated in patients with metastatic melanoma. Each patient received SCIB1 via intramuscular injection with electroporation. The trial was designed to find the safest dose of SCIB1 which induced immune/clinical responses in patients with or without tumour. Fifteen patients with tumor received SCIB1 doses of 0.4-8 mg whilst 20 fully-resected patients received 2-8 mg doses. Twelve patients elected to continue immunization every 3 months for up to 39 months. SCIB1 induced dose-dependent T cell responses in 88% of patients with no serious adverse effects or dose limiting toxicities. The intensity of the T cell responses was significantly higher in patients receiving 4 mg doses without tumor when compared to those with tumor (p

Published in

Links

Tools

Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Abstract